Terms: = Ovarian cancer AND NKX2-1, BCH, 7080, ENSG00000136352, P43699, TITF1, TEBP, BHC, NKX2A, TTF-1, NKX2_1, NK-2 AND Treatment
30 results:
1. Periostin's role in uterine leiomyoma development: a mini-review on the potential periostin poses as a pharmacological intervention for uterine leiomyoma.
Kiesler ZG; Hunter MI; Balboula AZ; Patterson AL
Arch Gynecol Obstet; 2024 May; 309(5):1825-1831. PubMed ID: 38441600
[TBL] [Abstract] [Full Text] [Related]
2. ER-positive and BRCA2-mutated breast cancer: a literature review.
Li PC; Zhu YF; Cao WM; Li B
Eur J Med Res; 2024 Jan; 29(1):30. PubMed ID: 38184581
[TBL] [Abstract] [Full Text] [Related]
3. Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives.
Salutari V; Giudice E; Lorusso D
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):9-17. PubMed ID: 38170548
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Approach to Neuroendocrine Neoplasm Associated With ovarian Teratoma.
Opalińska M; Sowa-Staszczak A; Olearska H; Ulatowska-Bialas M; Gilis-Januszewska A; Hubalewska-Dydejczyk A
Front Endocrinol (Lausanne); 2021; 12():770266. PubMed ID: 34917031
[TBL] [Abstract] [Full Text] [Related]
5. [The composition of ascites lymphocytes in high-grade serous ovarian cancer and its correlation with clinical features].
He TH; Zhang J; Yin ZN; Zhang X; Li Y; Wu Y; Li HJ; Liang HM; Xue LX; Guo HY
Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2375-2381. PubMed ID: 34404130
[No Abstract] [Full Text] [Related]
6. First case report of papillary thyroid carcinoma arising within a functional teratoma in Graves' disease patient.
Cheng CC; Ting-An ; Chang ; Yang WP
Gynecol Endocrinol; 2021 Oct; 37(10):955-958. PubMed ID: 34180765
[TBL] [Abstract] [Full Text] [Related]
7. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in ovarian cancer.
Ryu J; Thomas SN
Molecules; 2021 May; 26(9):. PubMed ID: 34063568
[TBL] [Abstract] [Full Text] [Related]
8. ovarian Vein Thrombosis: A Narrative Review.
Riva N; Calleja-Agius J
Hamostaseologie; 2021 Aug; 41(4):257-266. PubMed ID: 33348392
[TBL] [Abstract] [Full Text] [Related]
9. Updates in uterine artery embolization for leiomyomas.
Kim A; Arabkhazaeli M; Ulrich A; Lerner V; Shin JH
Curr Opin Obstet Gynecol; 2020 Aug; 32(4):269-276. PubMed ID: 32487798
[TBL] [Abstract] [Full Text] [Related]
10. ovarian metastases reported after adjuvant laparoscopic oophorectomies in breast cancer.
Cristian DA; Grama FA; Becheanu G; Popa I; Bratu AM; Burcoş T; Poalelungi CV; Şurlin V
Rom J Morphol Embryol; 2019; 60(3):913-920. PubMed ID: 31912104
[TBL] [Abstract] [Full Text] [Related]
11. ovarian cancer metastasis to the breast 18 years after the initial diagnosis: A case report.
Wang Z; Zhao D; Liu R; Zheng B
Medicine (Baltimore); 2019 Oct; 98(43):e17577. PubMed ID: 31651861
[TBL] [Abstract] [Full Text] [Related]
12. Exploring the Clinical Impact of Predictive Biomarkers in Serous ovarian Carcinomas.
Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM
Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218
[TBL] [Abstract] [Full Text] [Related]
13. Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed ovarian cancer.
Shuford S; Wilhelm C; Rayner M; Elrod A; Millard M; Mattingly C; Lotstein A; Smith AM; Guo QJ; O'Donnell L; Elder J; Puls L; Weroha SJ; Hou X; Zanfagnin V; Nick A; Stany MP; Maxwell GL; Conrads T; Sood AK; Orr D; Holmes LM; Gevaert M; Crosswell HE; DesRochers TM
Sci Rep; 2019 Aug; 9(1):11153. PubMed ID: 31371750
[TBL] [Abstract] [Full Text] [Related]
14. [Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.].
Angius G; Sepe P; Papa A; Tomao S; Tomao F
Recenti Prog Med; 2017 Jun; 108(6):269-281. PubMed ID: 28631775
[TBL] [Abstract] [Full Text] [Related]
15. Napsin-A, a Possible Diagnostic Marker for Differentiating Clear Cell ovarian Carcinoma From Other High-grade ovarian Carcinomas.
Alshenawy HA; Radi DA
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):605-610. PubMed ID: 28362708
[TBL] [Abstract] [Full Text] [Related]
16. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
Zub KA; Sousa MM; Sarno A; Sharma A; Demirovic A; Rao S; Young C; Aas PA; Ericsson I; Sundan A; Jensen ON; Slupphaug G
PLoS One; 2015; 10(3):e0119857. PubMed ID: 25769101
[TBL] [Abstract] [Full Text] [Related]
17. treatment of ovarian cancer beyond chemotherapy: are we hitting the target?
Garces ÁH; Dias MS; Paulino E; Ferreira CG; de Melo AC
Cancer Chemother Pharmacol; 2015 Feb; 75(2):221-34. PubMed ID: 25212538
[TBL] [Abstract] [Full Text] [Related]
18. [Maintenance therapy in patients with advanced epithelial ovarian cancer-impact of anti-angiogenic molecular targeted agents in progress].
Takeuchi S; Sugiyama T
Gan To Kagaku Ryoho; 2014 Aug; 41(8):937-43. PubMed ID: 25132025
[TBL] [Abstract] [Full Text] [Related]
19. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract] [Full Text] [Related]
20. A case of diaphragmatic clear cell carcinoma in a patient with a medical history of ovarian endometriosis.
Fujiu K; Miyamoto H; Hashimoto S; Suzuki N; Takano Y; Teranishi Y; Sakuma H; Suzuki H
Int J Clin Oncol; 2010 Oct; 15(5):489-92. PubMed ID: 20221659
[TBL] [Abstract] [Full Text] [Related]
[Next]
